Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15699345 | 1.00 | ATM (0.35) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16174139 | 1.00 | ATM (0.35) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12413176 | 1.00 | ATM (0.35) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6760034 | 1.00 | ATM (0.35) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24354973 | 0.82 | ATM (0.44) | ATMGAA | |
| SCHEMBL1101660 | 0.82 | ATM (0.44) | ATMGAA | |
| SCHEMBL10330907 | 0.82 | ATM (0.44) | ATMGAA | |
| SCHEMBL29108935 | 0.82 | ATM (0.44) | ATMGAA | |
| SCHEMBL13164365 | 0.82 | ATM (0.44) | ATMGAA | |
| SCHEMBL4072231 | 0.82 | ATM (0.44) | ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133174-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | OXTR, AVPR2, AVPR1B | ATM 2327/4885CHRM2 1024/4885CHRM4 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.